CureVac Announces Positive Results in Low Dose – 1 µg – Rabies Vaccine Clinical Phase 1 Study
- Low dose vaccination induced immune response in all subjects and was well tolerated
- Clinical results underline potency of CureVac’s technology platform
- Detailed results to be presented at an upcoming scientific conference
CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced positive data from an interim analysis of safety and immunogenicity in its Phase 1 study evaluating CV7202, a novel prophylactic mRNA based rabies vaccine.